Hironic하이로닉

Hironic's trailing profits are positive again after a 2024 loss, but the shares are down sharply over the past year.

Hironic, a KOSDAQ-listed medical and precision device maker, reports trailing-twelve-month revenue of ₩37.1B and net income of ₩4.5B through H1 2026, with a 12.2% net margin and low liabilities relative to equity. The share price of ₩4,070 is down 53.1% over one year and sits well below its 52-week high of ₩9,510. The company profile supplied is only a filing deadline notice, so the product and customer details are not in the data.

What stands out

• Annual revenue grew 1.4% in 2025 to ₩32.1B, after a 6.2% decline in 2024 when the company posted an operating loss of ₩4.8B.
• Net income was ₩3.2B in 2025, down from ₩8.2B in 2023, and the trailing figures are well above the 2024 loss.
• The company reports ₩11.3B in cash and no borrowings, with liabilities at 11.7% of equity, and trailing free cash flow of ₩1.2B.
• Valuation metrics show a P/E of 15.5 and P/B of 0.9, with no dividend yield, and the DCF base fair value of ₩4,873 sits above the current price.
• Recent headlines focus on North American entry, a US FDA approval for Helpnic expected to support consumables sales, and trade-show participation, with foreign ownership at 1.4%.

What to watch

• Whether the company's full-year 2026 results confirm the trailing profit recovery, given the 2024 loss and revenue growth of only 1.4% in 2025.
• Progress on the US FDA approval and North American expansion mentioned in recent news, which the data does not confirm with dates.
• Ongoing filings on stock purchase option grants, share cancellation and the amended annual report, which may affect share count and shareholder dilution.